Second Consensus on Treatment of Patients Recently Diagnosed With Mild Hypertension and Low Cardiovascular Risk.

[1]  Dorairaj Prabhakaran,et al.  2020 International Society of Hypertension global hypertension practice guidelines. , 2020, Journal of hypertension.

[2]  A. Morales-Salinas.  ¿Existen lagunas en la evidencia vinculada al tratamiento de la hipertensión leve de bajo riesgo cardiovascular? , 2019, Revista Española de Cardiología.

[3]  P. Whelton,et al.  Evidence Supporting the Blood Pressure Treatment Goal of Less Than 130/80 mm Hg. , 2019, Hypertension.

[4]  J. Tao,et al.  2018 Chinese Guidelines for Prevention and Treatment of Hypertension—A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension , 2019, Journal of geriatric cardiology : JGC.

[5]  Ji-Guang Wang.  Why is the Chinese hypertension guideline necessary? , 2019, Journal of geriatric cardiology : JGC.

[6]  S. Kaul.  How Strong Is the Evidence to Support Blood Pressure Treatment Goal of 130/80 mm Hg? , 2018, Circulation.

[7]  J. Laukkanen,et al.  Is ‘re-calibration’ of standard cardiovascular disease (CVD) risk algorithms the panacea to improved CVD risk prediction and prevention? , 2018, European heart journal.

[8]  J. Gallacher,et al.  Equalization of four cardiovascular risk algorithms after systematic recalibration: individual-participant meta-analysis of 86 prospective studies , 2018, European heart journal.

[9]  A. Viera,et al.  Association of Blood Pressure Classification in Young Adults Using the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline With Cardiovascular Events Later in Life , 2018, JAMA.

[10]  Satoshi Teramukai,et al.  Morning Home Blood Pressure and Cardiovascular Events in Japanese Hypertensive Patients , 2018, Hypertension.

[11]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[12]  E. Vartiainen.  The North Karelia Project: Cardiovascular disease prevention in Finland , 2018, Global cardiology science & practice.

[13]  Wilbert S Aronow,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[14]  K. Kario,et al.  Could 130/80 mm Hg Be Adopted as the Diagnostic Threshold and Management Goal of Hypertension in Consideration of the Characteristics of Asian Populations? , 2018, Hypertension.

[15]  C. Tsioufis,et al.  Treatment Thresholds and Targets in Hypertension: Different Readings of the Same Evidence? , 2018, Hypertension.

[16]  David M. Reboussin,et al.  Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines , 2018, Hypertension.

[17]  J. Williamson,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Hypertension.

[18]  K. Kario.  Differential Approaches are Much Needed for "Real World" Management of Hypertension in the Era of "Hypertension Paradox". , 2018, Current hypertension reviews.

[19]  K. Kario.  Global Impact of 2017 American Heart Association/American College of Cardiology Hypertension Guidelines: A Perspective From Japan. , 2018, Circulation.

[20]  P. López-Jaramillo,et al.  Guidelines on the management of arterial hypertension and related comorbidities in Latin America. , 2017, Journal of hypertension.

[21]  S. Yusuf,et al.  Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. , 2017, Current problems in cardiology.

[22]  K. Sliwa,et al.  Roadmap to achieve 25% hypertension control in Africa by 2025 , 2017, Cardiovascular journal of Africa.

[23]  P. Whelton,et al.  Using Predicted Cardiovascular Disease Risk in Conjunction With Blood Pressure to Guide Antihypertensive Medication Treatment. , 2017, Journal of the American College of Cardiology.

[24]  J. García,et al.  Evaluación de la validez de las funciones SCORE de bajo riesgo y calibrada para población española en las cohortes FRESCO , 2017 .

[25]  L. Malan,et al.  Recent advances in understanding hypertension development in sub-Saharan Africa , 2017, Journal of Human Hypertension.

[26]  D. Lloyd‐Jones,et al.  Global Risk Assessment to Guide Blood Pressure Management in Cardiovascular Disease Prevention , 2017, Hypertension.

[27]  G. de Simone,et al.  Left Ventricular Hypertrophy Regression During Antihypertensive Treatment in an Outpatient Clinic (the Campania Salute Network) , 2017, Journal of the American Heart Association.

[28]  F. Messerli,et al.  Isolated Systolic Hypertension: An Update After SPRINT. , 2016, The American journal of medicine.

[29]  S. Yusuf,et al.  Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. , 2016, The Lancet. Global health.

[30]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[31]  S. Yusuf,et al.  Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. , 2016, The New England journal of medicine.

[32]  J. Staessen,et al.  Characteristics of self-measured home blood pressure in a Nigerian urban community: the NIPREGH study , 2015, Blood pressure monitoring.

[33]  Veikko Salomaa,et al.  Twenty-five-year trends in myocardial infarction attack and mortality rates, and case-fatality, in six European populations , 2015, Heart.

[34]  M. Woodward,et al.  Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. , 2015, Annals of internal medicine.

[35]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk – overview and meta-analyses of randomized trials , 2014, Journal of hypertension.

[36]  G. Parati,et al.  Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels – overview and meta-analyses of randomized trials , 2014, Journal of hypertension.

[37]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[38]  E. Feskens,et al.  Healthy diet indicator and mortality in Eastern European populations: prospective evidence from the HAPIEE cohort , 2014, European Journal of Clinical Nutrition.

[39]  H. Hiraoka,et al.  High–normal blood pressure is associated with new-onset electrocardiographic left ventricular hypertrophy , 2014, Journal of Human Hypertension.

[40]  Isaac Subirana,et al.  Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: the FRESCO Study. , 2014, Preventive medicine.

[41]  A. Zanchetti,et al.  Relationships of different types of event to cardiovascular death in trials of antihypertensive treatment: an aid to definition of total cardiovascular disease risk in hypertension , 2014, Journal of hypertension.

[42]  B. Howard,et al.  Lack of Reduction of Left Ventricular Mass in Treated Hypertension: The Strong Heart Study , 2013, Journal of the American Heart Association.

[43]  Michael J Pencina,et al.  Cardiovascular Disease Risk Assessment: Insights from Framingham. , 2013, Global heart.

[44]  M. Carroll,et al.  Trends in lipids and lipoproteins in US adults, 1988-2010. , 2012, JAMA.

[45]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[46]  D. Lloyd‐Jones.  Improving the cardiovascular health of the US population. , 2012, JAMA.

[47]  F. Hu,et al.  Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. , 2012, JAMA.

[48]  M. Grau,et al.  Validez relativa de la estimación del riesgo cardiovascular a 10 años en una cohorte poblacional del estudio REGICOR , 2011 .

[49]  M. Litwin,et al.  Regression of target organ damage in children and adolescents with primary hypertension , 2010, Pediatric Nephrology.

[50]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[51]  M. Grau,et al.  La función calibrada REGICOR mejora la clasificación de los pacientes de alto riesgo tratados con estatinas respecto a Framingham y SCORE en la población española , 2009 .

[52]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[53]  R. Reneman,et al.  Non-invasive ultrasound in arterial wall dynamics in humans: what have we learned and what remains to be solved. , 2005, European heart journal.

[54]  J. Marrugat,et al.  Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada , 2003 .

[55]  Jiang He,et al.  Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. , 2002, JAMA.

[56]  M. Law,et al.  Risk factor thresholds: their existence under scrutiny , 2002 .

[57]  D. Levy,et al.  Impact of High-Normal Blood Pressure on the Risk of Cardiovascular Disease , 2001 .

[58]  D. Levy,et al.  Cross-classification of JNC VI blood pressure stages and risk groups in the Framingham Heart Study. , 1999, Archives of internal medicine.

[59]  Philip Greenland,et al.  Assessment of Cardiovascular Risk by Use of Multiple-Risk-Factor Assessment Equations , 1999 .

[60]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[61]  Helmut Baumgartner,et al.  The 2013 ESH/ESC guidelines for the management of arterial hypertension , 2013 .

[62]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.